UnitedHealth Group IncorporatedNYSE: UNH

JPMorgan raised its UnitedHealth price target to $466 from $420, maintaining an "Overweight" rating, as the stock has attracted six analyst upgrades in two weeks through mid-June 2026. The shares rebounded to approximately $407 from a 52-week low of $234.60, recovering roughly 73% but still trading 32% below the November 2024 all-time high of $603.20. Q1 2026 results beat estimates: revenue of $111.7 billion (+2% YoY), adjusted EPS of $7.23, with full-year 2026 adjusted EPS guidance raised to greater than $18.25. The company also lifted its quarterly dividend to $2.32 per share. However, the Department of Justice antitrust investigation into UnitedHealth's Optum division remains the most significant binary risk — any escalation involving forced divestiture of Optum assets would materially invalidate the investment thesis. Q2 2026 earnings are scheduled for July 16, 2026. Conviction-weighted targets from JPMorgan, BofA, and Morgan Stanley cluster between $450 and $466.

JPMorgan resets UnitedHealth stock target for 2026thestreet.comUnitedHealth Stock Analysis: June 2026 Recovery and Risksen.cryptonomist.chUnitedHealth Group (UNH) Stock Could Be 55% Undervalued After EPS Guidance Raise And Dividend Hikesimplywall.st

No material news in the last 48 hours.

No material news in the last 48 hours.

No material news in the last 48 hours.

UnitedHealth shares surged 5.2% amid growing optimism about the health insurer's improving prospects, trading around $405-$409. JPMorgan raised its price target to $466 from $420 and kept an Overweight rating. The company introduced Avery, an AI healthcare chatbot designed to coordinate care for members, and is seeing positive momentum from multiple analyst upgrades and a proposed insulin-pricing settlement. Optum Rx also said it will align pharmacy payment models more closely to manufacturer pricing actions by January 2028. UnitedHealth will report Q2 2026 results on July 16, 2026 before market open. The stock trades at ~30.8x earnings with a ~2.2% yield. The risk is that despite the rally, the broader analyst average 12-month target (~$407) sits near the current price, suggesting much of the optimism may already be priced in ahead of earnings.

UnitedHealth Group Announces Earnings Release Datebusinesswire.comUnitedHealth Group (UNH) Stock Price & Overviewstockanalysis.comUNH: UnitedHealth Group Inc - Stock Price, Quote and Newscnbc.com

Berkshire Hathaway disclosed in its May 15 13F that it fully exited its UnitedHealth position in Q1 2026 (less than a year after revealing the stake in August 2025). UNH shares fell in early trading May 18, closing at $391.13. Analysts attribute the move to Berkshire leadership transition rather than a fundamental negative view. Operationally, UnitedHealthcare cut prior authorization requirements by 30% (May 5), Optum Rx introduced the industry's first transparent pharmacy care model (May 11), and Bloomberg reported (May 15) that UnitedHealth is tracking employee AI usage in Optum services. Stock remains up ~20% YTD with 22 Buy/1 Sell ratings.

UnitedHealth (UNH): Up 20% in 2026, But Buffett's Heir Just Walked Out - FXLeadersfxleaders.comUnitedHealth Tracks Workers' AI Use - Bloombergbloomberg.comLatest Updates - UnitedHealth Groupunitedhealthgroup.com

UNH shares fell over 2% on May 18 after Berkshire Hathaway revealed in a May 15 filing that it had fully sold its UnitedHealth stake during Q1 portfolio reshuffling. The stock had just reached a 52-week high of $404.14 on May 13, with month-to-date gains near 30% and YTD ~21%. Fundamentals remain strong: Q1 2026 revenue of $111.7B (+2% YoY) and adjusted EPS of $7.23 beat the $6.76 consensus, with full-year guidance raised. UnitedHealthcare announced cuts of 30% to prior authorization requirements on May 5, and Optum Rx launched a transparent pharmacy care model on May 11. UnitedHealth confirmed it is the subject of DOJ criminal and civil probes into Medicare Advantage billing practices. Risk: regulatory/DOJ overhang and political pressure on PBM economics.

UnitedHealth Falls After Berkshire Sells Stake in Health Insurermoney.usnews.comUnitedHealth (UNH): Up 20% in 2026, But Buffett's Heir Just Walked Out the Doorfxleaders.comUnitedHealthcare Cuts Prior Authorization Requirements by 30%unitedhealthgroup.com

Bloomberg reported May 15 that UnitedHealth Group is tracking how often employees use AI tools as part of a company-wide push to embed AI across operations, signaling an aggressive cost-and-productivity transformation. UnitedHealthcare announced on May 5 that it has cut prior authorization requirements by 30%, and Optum Rx introduced what it calls the industry's first transparent pharmacy care model on May 11. UNH shares traded as low as $375 intraday May 18 before closing at $398.80, with the stock up 9.6% over seven sessions. Q1 results posted April 21 showed 2% revenue growth and management raised 2026 adjusted EPS guidance to at least $18.25. Risk: ongoing antitrust scrutiny, Medicare Advantage risk-coding investigations, coverage denial scrutiny, and Berkshire Hathaway recently sold its entire stake amid rising medical costs.

UnitedHealth Tracks Workers' AI Use in Push to Transform Companybloomberg.comUnitedHealth Group Stock (UNH) Opinions on Q1 2026 Earnings Beat and Guidance Raisequiverquant.comAmerica's Health Rankings 2026 Senior Reportunitedhealthgroup.com

Bloomberg reported on May 15 that UnitedHealth Group is tracking how often some employees use AI tools as part of a sweeping push to embed the technology across operations — a notable management/operational signal as it tries to lower costs. Shares pulled back from a May 13 52-week high near $404 to roughly $375 by May 18, with weakness tied in part to Berkshire Hathaway's complete exit from its UNH stake, regulatory overhangs and Medicare margin pressures. On the positive side, UnitedHealthcare announced it is eliminating prior-authorization requirements for 30% of services (and 70%+ will move to a standardized submission process by year-end), and Optum Rx introduced a transparent pharmacy care model. Bank of America raised its target to $420 from $380 on May 13. Risk: regulatory and reimbursement pressure plus continued investor confidence questions.

UnitedHealth Tracks Workers' AI Use in Push to Transform Companybloomberg.comUnitedHealthcare Cuts Prior Authorization Requirements by 30%unitedhealthgroup.comUnitedHealth Group (NYSE:UNH) Reaches New 12-Month Highmarketbeat.com

On May 13, UnitedHealth's Optum Rx sued the state of California over a new PBM law, arguing it would raise employer plan costs by ~$1,800 per participant annually; the law applies to self-insured employer plans, insurers, and public plans. Optum Rx also unveiled a transparent fee-based PBM model launching in 2027 that removes spread pricing and shifts to per-member fees. UNH shares hit a 52-week high of $404.15, up ~30% over the past month and ~23% YTD, after Q1 revenue grew 2% YoY to $111.7B with adjusted EPS of $7.23 above consensus, and management raised FY26 adjusted EPS guidance to >=$18.25 (from >=$17.75). Goldman Sachs added UNH to its Conviction List; BofA raised its PT to $420 from $380. UnitedHealthcare is also eliminating ~30% of prior authorization requirements. Risk: state-level PBM regulation and Medicare Advantage cost trends.

UnitedHealth's Optum Rx sues California over PBM lawbenefitspro.comGoldman Sachs Just Added UnitedHealth (UNH) to Its Conviction Listtheglobeandmail.comUnitedHealth Group (UNH) Stock Surges to 52-Week Peak Following Impressive Q1 Performanceblockonomi.com

UnitedHealth Group reached a 52-week high of $404.14 on May 13, 2026 and closed at $399.36, up ~47% from its March 2026 low of $270.59. On May 13, Optum Rx disclosed a new transparent, fee-based pricing model that decouples profits from drug prices, getting ahead of PBM reform legislation. On May 5, UNH announced it would eliminate prior authorization requirements for 30% of medical services by year-end, responding to regulatory and public backlash. Goldman Sachs added UNH to its U.S. Conviction Buy list citing a bottoming Medicare Advantage underwriting cycle. UNH cut MA membership by 1.3 million in 2026 to repair margins; medical care ratio improved to 83.9% from 84.8%. UNH is investing $1.5B in AI in 2026. Risk: ongoing DOJ antitrust investigations, False Claims Act litigation, and Medicaid margin pressures remain material overhangs.

Goldman Sachs Just Added UnitedHealth (UNH) to Its Conviction Listfool.comUnitedHealth's Optum Rx Says Profits Won't Depend on Drug Pricesbloomberg.comUNH Stock Finally Breaks Above $400 as Medicare Outlook and Margins Improvefxleaders.com

UnitedHealth Group shares climbed 4.3% to $396.39 on May 12 and presented at the Bank of America Securities Health Care Conference. The stock has staged a remarkable recovery, soaring 47%+ from its March 27 low of $259 (vs. starting the year at $336). Q1 2026 results showed revenue rising 2% YoY to $111.7B, with reported EPS of $6.90 and adjusted EPS of $7.23, both above expectations. Medical Care Ratio improved to 83.9% in Q1 from 88.9% in the prior quarter. UnitedHealth cut Medicare Advantage membership by 1.3 million in 2026 to improve margins, and is rolling out a fee-based pharmacy benefit model through Optum Rx. 25 analysts maintain a Buy consensus rating.

Is It Too Late to Buy UnitedHealth After 4.3% Rally?gurufocus.comIs UnitedHealth a Buy, Sell, or Hold in 2026?fool.comUNH plans BofA health conference webcaststocktitan.net

UnitedHealth reported Q1 2026 revenue of $111.7B and adjusted EPS of $7.23, beating the $6.65 consensus by 9%, and raised FY 2026 adjusted EPS guidance to greater than $18.25 (vs prior $17.75). The company drew strong investor attention by announcing it will eliminate prior authorization requirements for 30% of healthcare services, easing administrative friction for physicians. UNH agreed to acquire Alegeus Technologies and completed the sale of the Optum UK business with $400M of net proceeds committed to the United Health Foundation. Shares rallied sharply (30-day return +20.15%, 90-day +33.65%), trading $376-$385 on May 12. Senior leaders are presenting at the BofA Securities Healthcare Conference on May 12. Consensus rating is Buy with average price target ~$378.

UnitedHealth Group Reports First Quarter 2026 Resultsbusinesswire.comUNH Prior Authorization Policy Change (Stocktwits)stocktwits.comUnitedHealth Lifts 2026 Outlook After Q1 Results (StockTitan)stocktitan.net